好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2012 Annual Meeting | Vascular Contributions to Cognitive Impairment and Dementia: Diagnosis, Prevention, and Treatments

Monday 04/23/12
09:00 AM - 01:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
AM Half-Day Course
Philip B. Gorelick, MD, MPH, FAAN
Participants should become familiar with the different forms of VCI and how to recognize them, screening for VCI and other forms of cognitive impairment, key recommendations from the AHA/ASA guideline statement for vascular contributions to cognitive impairment and dementa, and practical implications of the AHA/ASA guideline statement.
No CME available
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Subspecialty in Focus
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist
Case-based, Didactic, Interactive

Program Evaluations

Event Timeline
09:00 AM - 09:45 AM Vascular Cognitive Impairment (VCI): Common Forms, Criteria, Clinical Features and Routine Diagnostic Tests
Steven M. Greenberg, MD, PhD, FAAN
09:45 AM - 09:55 AM Questions and Answers
Steven M. Greenberg, MD, PhD, FAAN
09:55 AM - 10:25 AM Vascular Contributions to Cognitive Impairment and Dementia: A New Guidance Statement from AHA
Philip B. Gorelick, MD, MPH, FAAN
10:25 AM - 10:30 AM Questions and Answers
Philip B. Gorelick, MD, MPH, FAAN
10:30 AM - 10:45 AM Break
10:45 AM - 11:30 AM Vascular Contributions to Cognitive Impairment and Dementia: Implications for the Practicing Physician and Health Care Provider
Rebbeca Grysiewicz, DO
11:30 AM - 11:40 AM Questions and Answers
Rebbeca Grysiewicz, DO
11:40 AM - 12:25 AM Advances in Neuroimaging in the Diagnosis of VCI and Related Dementias
Sandra E. Black, MD, FAAN
12:25 PM - 12:35 PM Questions and Answers
Sandra E. Black, MD, FAAN
12:35 PM - 01:00 PM Expert Panel Discussion and Audience Case Presentations
Faculty Disclosures
Philip B. Gorelick, MD, MPH, FAAN Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AMGEN. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Thorek Memorial Hospital. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Thorek Memorial Hospital.
Steven M. Greenberg, MD, PhD, FAAN Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Sandra E. Black, MD, FAAN Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.
Rebbeca Grysiewicz, DO No disclosure on file